Onconetix, Inc. Increase (Decrease) in Accounts Receivable
Onconetix, Inc. (ONCO) reported Increase (Decrease) in Accounts Receivable of -$312.19 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-13
- Onconetix, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$41.45K.
- Onconetix, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$270.74K.
- Onconetix, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $293.93K.
- Onconetix, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$9.56K.
- Onconetix, Inc. increase (decrease) in accounts receivable for fiscal 2025 was $268.69K.
- Onconetix, Inc. increase (decrease) in accounts receivable for fiscal 2024 was -$116.68K, a 287.32% decline from fiscal 2023.
- Onconetix, Inc. increase (decrease) in accounts receivable for fiscal 2023 was $62.29K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$41.45K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$312.19K 10-Q · filed 2026-08-13 | -$18.26K derived: sum of 3 quarters · filed 2026-08-13 | -$27.82K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$270.74K 10-Q · filed 2026-05-13 | $23.19K derived: sum of 2 quarters · filed 2026-05-13 | $13.63K derived: sum of 3 quarters · filed 2026-05-13 | $7.40K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $293.93K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $284.37K derived: sum of 2 quarters · filed 2026-03-13 | $278.14K derived: sum of 3 quarters · filed 2026-08-13 | $268.69K 10-K · filed 2026-03-13 |
| 2025-09-30 | -$9.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$15.79K derived: sum of 2 quarters · filed 2026-08-13 | -$25.24K 10-Q · filed 2025-11-13 | -$92.84K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$6.23K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$15.69K 10-Q · filed 2026-08-13 | -$83.28K derived: sum of 3 quarters · filed 2026-08-13 | -$163.86K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$9.45K 10-Q · filed 2026-05-13 | -$77.05K derived: sum of 2 quarters · filed 2026-05-13 | -$157.63K derived: sum of 3 quarters · filed 2026-05-13 | -$242.89K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$67.60K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$148.18K derived: sum of 2 quarters · filed 2026-03-13 | -$233.44K derived: sum of 3 quarters · filed 2026-03-13 | -$116.68K 10-K · filed 2026-03-13 |
| 2024-09-30 | -$80.58K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$165.84K derived: sum of 2 quarters · filed 2025-11-13 | -$49.08K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | -$85.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $31.50K 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $116.76K 10-Q · filed 2025-06-12 | |||
| 2023-12-31 | $62.29K 10-K · filed 2025-06-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |